AbCellera Biologics Inc.

AbCellera Biologics Inc. is a clinical-stage biotechnology company that discovers and develops antibody medicines for diseases with high unmet medical need. The company built an integrated antibody-discovery platform and is now using it both for partnered programs and for its own internal pipeline of drug candidates. Its business model combines upfront research fees, milestone payments, royalties, and other downstream participation from partners with the longer-term goal of creating proprietary medicines. In 2025, AbCellera advanced its first internal clinical candidates, ABCL635 and ABCL575, and opened a clinical manufacturing facility to support its transition from a discovery platform into an integrated drug developer.

−264,4 %

−194,9 %

+160,6 %

11.32

11.23

— AbCellera Biologics Inc.
	%
Partnered discovery services	45% Discovery research, technology access, and program support provided to biopharma partners under collaboration agreements.
Milestone and royalty economics	30% Upfront, clinical, regulatory, commercial milestone payments and royalties tied to partner programs and licensed assets.
Internal drug development	15% AbCellera-owned antibody programs advanced through preclinical and clinical development, including ABCL635 and ABCL575.
Licensing and IP monetization	5% Licenses, patent settlements, and other intellectual property monetization such as the Bruker agreement.
Manufacturing and platform infrastructure	5% Clinical manufacturing and related infrastructure that supports internal programs and future development scale-up.

AbCellera sells primarily to biopharmaceutical companies that need antibody discovery, program advancement, and access...

Biopharmaceutical partnersprimary
Companies that outsource antibody discovery and early program work to AbCellera because they need difficult targets addressed faster and with lower internal build-out.
Licensees and IP counterpartiessecondary
Companies that pay for platform licenses, patent rights, or settlement-based access to AbCellera intellectual property.
Commercialized program partnerssecondary
Partners whose approved products can generate royalties for AbCellera if the discovered molecule reaches market.
Internal pipeline stakeholdersemerging
Clinical investigators, regulators, and future commercialization partners involved in advancing AbCellera-owned assets such as ABCL635 and ABCL575.

AbCellera is headquartered in the United States, but its operating footprint is meaningfully cross-border because its...

•United States headquarters and corporate decision-making base
•Canada is important for early clinical trials of ABCL635 and ABCL575
•Clinical manufacturing facility supports in-house development and supply control
•Partner and licensing revenue can come from global counterparties
•Worldwide royalty exposure exists through partner commercialization and IP licenses

AbCellera's strategy is to convert its antibody-discovery platform into a broader integrated drug-development engine...

Advance ABCL635 and ABCL575 through early clinical developmentshort-term

These programs validate the shift from pure platform monetization to owned asset creation and can create higher long-term value if clinical data are positive.

Build and utilize integrated manufacturing capabilityshort-term

Owning clinical manufacturing reduces dependence on third parties and supports faster, more controlled development of internal programs.

Expand downstream economics from partnered programsmedium-term

Milestones, royalties, and equity-like participation can generate high-margin value without full commercialization risk.

Selectively out-license or partner internal assetsmedium-term

Management evaluates each program individually to maximize development and commercial potential while balancing risk and capital intensity.

AbCellera faces the core risks of clinical-stage biotechnology: its internal programs may fail in preclinical or...

high

Clinical development failure

The company's owned pipeline is still early-stage, so negative safety or efficacy data could eliminate expected value from internal programs.

Scope: ABCL635, ABCL575, ABCL688, ABCL386
Materiality: high

high

Manufacturing and quality-control issues

Biologic products require complex process validation, contamination control, and reliable supply chains, any of which can delay trials or commercialization.

Scope: Clinical manufacturing and third-party biologics production
Materiality: high

high

Partner dependence

A large part of revenue potential comes from partners advancing programs to milestones or market, which AbCellera does not control.

Scope: Research fees, milestones, royalties
Materiality: high

medium

Patent and litigation risk

The company must defend and monetize its IP portfolio, and disputes can create legal expense or constrain commercialization.

Scope: Bruker litigation and broader patent portfolio
Materiality: medium

medium

Commercial adoption risk

Even approved antibody medicines may not achieve broad physician, patient, or payer acceptance, limiting royalty upside.

Scope: Future partnered or owned products
Materiality: medium

ASC 606 revenue recognition

Can materially shift revenue between quarters and years

Milestone and royalty estimation

Creates highly variable and hard-to-predict revenue

Goodwill and intangible impairment

Could produce non-cash charges that materially affect earnings

Stock-based compensation

Raises operating expense and affects comparability

Contingent obligations and litigation settlement accounting

Can affect both revenue and future cash flow visibility

AbCellera Biologics Inc.

Clinical development failure

Manufacturing and quality-control issues

Partner dependence

Patent and litigation risk

Commercial adoption risk

Absci Corp

Cabaletta Bio, Inc.

Abpro Holdings, Inc.

Aptevo Therapeutics Inc.

Apogee Therapeutics, Inc.

Celularity Inc